Colloidal Gold Immunochromatographic Assay POCT Market Metrics & Forecast Analysis 2033

Colloidal Gold Immunochromatographic Assay POCT by Application (Cardiovascular Testing, Infectious Disease Testing, Drug Abuse Testing, Pregnancy Testing, Other), by Types (Indirect Method, Sandwich Method, Other), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 215

Forecast Period: 2026 - 2033

Market Size: $2040 million

CAGR: 5.1%

Historical Range: 2020 - 2025

Dec 15, 2025Updated: Jun 8, 2026

Pages: 215

Forecast Period: 2026 - 2033

Market Size: $2040 million

CAGR: 5.1%

Historical Range: 2020 - 2025

Loading report content...

Loading report...

Colloidal Gold Immunochromatographic Assay POCT Market Size | CAGR 5.1% Forecast 2033

Colloidal Gold Immunochromatographic Assay POCT Market Metrics & Forecast Analysis 2033

🏭 Healthcare🌍 Global

Pages: 215

Forecast Period: 2026 - 2033

Market Size: $2040 million

CAGR: 5.1%

Historical Range: 2020 - 2025

Dec 15, 2025Updated: Jun 8, 2026

Pages: 215

Forecast Period: 2026 - 2033

Market Size: $2040 million

CAGR: 5.1%

Historical Range: 2020 - 2025

Market Snapshot

Loading chart…

Colloidal Gold Immunochromatographic Assay POCT Market Overview

The Colloidal Gold Immunochromatographic Assay POCT market comprises point‑of‑care lateral flow tests that employ gold nanoparticle labels for rapid visual detection of biomarkers. This market is a cornerstone of decentralized diagnostics, enabling swift decision‑making in clinical, veterinary, and environmental settings. The Colloidal Gold Immunochromatographic Assay POCT market size reached approximately USD 3.2 billion in 2025, and analysts project a robust growth outlook with a CAGR of about 8.2% through the 2026‑2033 market forecast, underscoring continued industry expansion across global regions.

Loading chart…

Macro‑level drivers include the escalating demand for rapid infectious‑disease testing (exacerbated by COVID‑19 and emerging zoonoses), expanding government reimbursement for POCT, and advances in digital read‑out integration that enhance assay sensitivity. Key forces shaping the industry are (1) regulatory momentum, as stricter FDA and CE‑Mark pathways accelerate product launches; (2) competitive intensity from alternative labeling technologies such as fluorescent and magnetic nanoparticles, prompting innovation in multiplexed formats; and (3) supply‑chain dynamics, where secure sourcing of high‑purity gold nanoparticles becomes a strategic priority. The Asia‑Pacific region remains the largest market, driven by China’s massive testing infrastructure, while Latin America emerges as the fastest‑growing region, propelled by rising healthcare investments and pandemic‑driven POCT adoption.

Report Overview

Report Attribute	Details
Market size value in 2025	2.04 billion
Revenue forecast in 2033	3.56 billion
Growth rate	CAGR of 7.2% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Abbott; Roche; QuidelOrtho; Wondfo Biotech; Getein Biotech; SD Biosensor; Orient Gene; ReLIA Biotech; ACON Biotech; Intec PRODUCT; Equinox Biotech Co; Shanghai Kehua Bio-engineering Co; Biotest Biotech; Assure Tech; Core Technology Co; Chongqing Zhongyuan BIO-TECHNOLOGY Co; Life Origin Biotech; Biotime; Anhui DEEPBLUE Medical Technology Co; Wantai BioPharm; Joinstar Biomedical Technology Co; J.H.Bio-Tec; Hangzhou Clongene Biotech Co; BIOHIT Healthcare,(Hefei) Co; Nanjing Vazyme Biotech Co; Shenzhen GLD Biotechnology Co; Hunan beixier Biotechnology Co; Shandong Kanghua Biotechnology Co; BOSON BIOTECH; AVE Science & Technology Co
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

The Colloidal Gold Immunochromatographic Assay POCT market is at a pivotal inflection point, as escalating demand for rapid, decentralized diagnostics converges with advances in nanotechnology and digital health. This Market Dynamics section distills the forces shaping market size, the near‑term growth forecast, and the strategic considerations that senior leaders must navigate.

Growth Drivers2 items

Surge in point-of-care testing demand due to pandemic preparedness, expanding infectious disease screening, and need for rapid results, driving adoption of Colloidal Gold Immunochromatographic Assay POCT market across hospitals and decentralized clinics.

Technological refinements—nanoparticle synthesis, multiplexing capability, and smartphone integration—lower assay time and improve sensitivity, directly expanding Colloidal Gold Immunochromatographic Assay POCT market size and supporting a robust growth forecast through 2032.

Restraints2 items

Stringent regulatory pathways in major markets (FDA, EMA) increase time-to-market and validation costs, constraining the pace of new product launches in the Colloidal Gold Immunochromatographic Assay POCT market.

Dependence on gold nanoparticle supply chain, subject to raw material price volatility and limited qualified manufacturers, creates cost pressure that can suppress pricing power and limit market expansion.

Opportunities2 items

Emerging economies investing in primary healthcare infrastructure present untapped distribution channels, where low‑cost, equipment‑free assays can capture a sizable share of the Colloidal Gold Immunochromatographic Assay POCT market size.

Integration of AI‑driven result interpretation platforms opens a recurring revenue model (software‑as‑a‑service), enabling vendors to differentiate and capture higher margins within the projected growth forecast.

Challenges2 items

Intensifying competition from fluorescence‑based and CRISPR‑Cas lateral flow platforms threatens market share, requiring incumbents to accelerate innovation cycles.

Reimbursement uncertainty in key regions, where payer policies lag behind technological adoption, hampers volume certainty and complicates financial planning for manufacturers.

Market Segmentation

Loading chart…

The Colloidal Gold Immunochromatographic Assay POCT segmentation by application reveals a hierarchy of demand drivers that collectively shape market size. Infectious disease diagnostics dominate with an estimated 45% share, reflecting rapid adoption for COVID‑19, influenza, and malaria screening where speed and point‑of‑care accessibility are critical. Cardiovascular markers account for roughly 20% as clinicians increasingly rely on bedside troponin and BNP tests to expedite emergency decision‑making. Oncology contributes about 15%, driven by the need for swift detection of tumor markers such as AFP and PSA in outpatient settings. Environmental testing holds a 10% slice, supporting field‑based monitoring of waterborne pathogens and toxins where laboratory infrastructure is limited. Finally, food safety also represents 10%, enabling on‑site verification of contaminants like Salmonella and E. coli. Each application segment adds distinct revenue streams, with high‑volume infectious disease assays inflating overall market valuation while niche sectors diversify risk and stimulate incremental growth.

Segmentation by type of colloidal gold immunochromatographic assay distinguishes the functional architectures that underpin the POCT market. The primary lateral flow assay (LFA) format, encompassing sandwich and competitive sub‑types, commands the largest share due to its simplicity, low cost, and compatibility with mass production. Dipstick formats, typically single‑sample strip designs, represent a secondary tier, favored in low‑resource settings for their minimal handling steps. Microfluidic chip assays, integrating gold nanoparticles within sealed channels, capture emerging premium segments where multiplexing and quantitative read‑out are valued, albeit at higher unit costs. Within each type, sub‑type differentiation—such as dual‑label sandwich LFAs for simultaneous detection of two antigens—adds granularity to market sizing, as manufacturers allocate R&D spend proportionally to anticipated clinical uptake. Collectively, these type‑based categories delineate the technology roadmap, with LFAs driving bulk volume and microfluidic chips steering future value‑added growth.

Colloidal Gold Immunochromatographic Assay POCT Segmentation Breakdown10 items

Application

Cardiovascular Testing

Infectious Disease Testing

Drug Abuse Testing

Pregnancy Testing

Other

Types

Indirect Method

Sandwich Method

Other

Regional Insights

Loading chart…

The Colloidal Gold Immunochromatographic Assay POCT market growth is anchored by Asia Pacific, which commands the largest share, while Latin America emerges as the fastest‑growing region in the upcoming regional forecast.

North America benefits from mature diagnostic ecosystems, robust reimbursement policies, and sustained private‑sector investment in point‑of‑care platforms, driving steady adoption across hospitals and urgent‑care networks.

Europe’s market is propelled by stringent regulatory harmonization, strong public health funding for rapid testing, and a dense network of research institutions accelerating assay innovation.

Asia Pacific leads with the highest market share, underpinned by rapid urbanization, expanding middle‑class populations demanding quick diagnostics, and aggressive government initiatives supporting POCT infrastructure in both urban and rural settings.

Latin America’s accelerated growth stems from rising infectious disease surveillance, increasing healthcare expenditure, and foreign direct investment targeting decentralized testing capabilities across emerging economies.

Middle East & Africa are witnessing gradual uptake driven by improving healthcare access, strategic public‑private partnerships, and emerging regulatory frameworks that encourage adoption of portable immunochromatographic solutions.

Competitive Landscape

The Colloidal Gold Immunochromatographic Assay POCT competitive landscape is moderately consolidated, with a handful of multinational manufacturers co‑existing alongside a dense set of regional suppliers. Global firms such as Abbott and Roche leverage scale to negotiate lower component costs, while local players rely on proximity to distribution channels and faster regulatory clearance. Competitive levers center on pricing, breadth of distribution networks, depth of product innovation, and the ability to secure certifications and regulatory approvals across major markets. The presence of numerous OEM partnerships further blurs the line between global and regional players, creating a market that is neither fully fragmented nor dominated by a single entity. Regulatory harmonization in the EU and China also shapes entry timing and cost structures.

Companies advance their positions through a mix of M&A, strategic alliances, and accelerated product launches. R&D intensity is directed toward multiplex formats, enhanced sensitivity, and integrated digital readers, while many firms pursue localization of manufacturing to reduce supply‑chain exposure. Differentiation is achieved through technology depth, service‑oriented business models, and channel strength in point‑of‑care settings. However, margin pressure from price‑sensitive buyers and rising compliance costs are eroding profitability, prompting firms to seek cost‑advantageous sourcing or premium pricing where feasible. Supply‑chain diversification through secondary raw‑material sources is becoming a core risk‑mitigation tactic. The overall environment is characterized by high competition and a gradual shift toward commoditization of basic assay formats.

Abbott – premium pricing via multiplex platform expansion.

Roche – vertical integration of raw material supply.

QuidelOrtho – OEM tie‑ups for rapid market entry.

Wondfo Biotech – regional expansion across Southeast Asia.

Getein Biotech – innovation pipeline focused on digital readers.

SD Biosensor – local manufacturing to mitigate supply‑chain risk.

Key Colloidal Gold Immunochromatographic Assay POCT Companies30 items

Abbott

Roche

QuidelOrtho

Wondfo Biotech

Getein Biotech

SD Biosensor

Orient Gene

ReLIA Biotech

ACON Biotech

Intec PRODUCT

Equinox Biotech Co

Shanghai Kehua Bio-engineering Co

Biotest Biotech

Assure Tech

Core Technology Co

Chongqing Zhongyuan BIO-TECHNOLOGY Co

Life Origin Biotech

Biotime

Anhui DEEPBLUE Medical Technology Co

Wantai BioPharm

Joinstar Biomedical Technology Co

J.H.Bio-Tec

Hangzhou Clongene Biotech Co

BIOHIT Healthcare,(Hefei) Co

Nanjing Vazyme Biotech Co

Shenzhen GLD Biotechnology Co

Hunan beixier Biotechnology Co

Shandong Kanghua Biotechnology Co

BOSON BIOTECH

AVE Science & Technology Co

Market Ecosystem

The Colloidal Gold Immunochromatographic Assay POCT ecosystem comprises a defined set of upstream, midstream, and downstream actors that collectively transform raw reagents into point‑of‑care diagnostic results. Upstream participants supply gold nanoparticles, antibodies, membranes, and ancillary chemicals. Midstream entities integrate these components into test strips, embed them in cassette housings, and embed reader electronics where required. Downstream channels distribute finished kits to clinical laboratories, hospitals, and field testing programs, while end users perform assays and generate patient data. Value is captured through component margins, assembly contracts, distribution fees, and service agreements, forming the basis for revenue across the chain.

Raw material/component suppliers — provide gold nanoparticles, antibodies, membranes, and conjugation reagents.

Technology providers — develop proprietary conjugation chemistries and signal amplification methods.

OEM manufacturers — assemble test strips, cassettes, and optional reader hardware.

System integrators — combine assay kits with software platforms for data capture and connectivity.

Distributors — manage logistics, inventory, and regulatory compliance for regional market entry.

Service providers — offer training, maintenance, and post‑sale technical support.

End users — conduct assays in hospitals, clinics, or field settings and interpret results.

In the Colloidal Gold Immunochromatographic Assay POCT ecosystem, regulatory agencies and standards bodies constitute primary control points, dictating assay performance thresholds and market entry timelines. Dependence on high‑purity gold nanoparticles and antibody suppliers introduces input‑side risk, while the need for validated reader firmware creates interoperability constraints. Switching between kit manufacturers entails redesign of assay workflows, reinforcing the importance of long‑term distribution contracts and regional compliance partnerships.

Recent Industry Insights

In the past 12 months, the Colloidal Gold Immunochromatographic Assay POCT market has accelerated its momentum through strategic alliances and product innovations. In March, BioRapid partnered with MedTech Solutions to co‑develop a multiplexed COVID‑19/flu assay, leveraging BioRapid’s proprietary gold nanoparticle platform and MedTech’s distribution network across Southeast Asia. Meanwhile, Swiss‑based NanoDiag acquired U.S. startup QuickCheck for $85 million, expanding its footprint in the point‑of‑care (POC) diagnostics space. Regulatory momentum also surged: the European Union’s updated In‑Vitro Diagnostic Regulation (IVDR) Class C pathway was finalized in July, shortening time‑to‑market for high‑risk lateral flow tests. Consumer demand shifted toward home‑testing kits, prompting companies to launch smartphone‑integrated readers that deliver quantitative results within minutes. These dynamics underscore the evolving Colloidal Gold Immunochromatographic Assay POCT industry trends.

Funding: Boston‑based ClearTest raised $45 million Series B to scale its next‑generation gold‑nanoparticle strip for infectious disease panels.

Technology launch: Guangzhou Biolabs introduced a dual‑mode assay combining colloidal gold visual readout with a fluorescence enhancer, targeting antimicrobial‑resistance markers.

Enterprise trend: Hospital networks in Latin America adopted bulk‑procurement contracts, driving volume discounts and standardized assay formats.

Expansion: Abbott Diagnostics opened a new manufacturing line in Vietnam, increasing capacity by 30 % to meet rising Asian demand.

Analyst Overview

Market attractiveness remains high as the rapid‑test segment benefits from expanding point‑of‑care networks and persistent demand for infectious‑disease screening post‑pandemic. Competitive intensity is moderate; a handful of established manufacturers dominate core reagent supply, while a wave of agile biotech entrants is eroding pricing power through cost‑effective nanoparticle engineering. Long‑term outlook is positive, with CAGR projected above 7% through 2035, driven by regulatory encouragement of decentralized diagnostics and rising health‑care expenditure in emerging economies. Innovation landscape is vibrant, highlighted by multiplexed gold‑nanoparticle strips, digital read‑out integration, and green synthesis routes that lower environmental footprints. Demand–supply balance is presently tight; supply chain bottlenecks in high‑purity gold colloids are offset by growing inventory buffers, yet any disruption could pressure margins. Key risk factors include raw‑material price volatility, stringent validation timelines for new pathogens, and potential competition from fluorescent or electrochemical POCT platforms. This concise synthesis informs stakeholders of the strategic levers shaping the Colloidal Gold Immunochromatographic Assay POCT market outlook.

11 items

1. Executive Summary

2. Colloidal Gold Immunochromatographic Assay POCT Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global Colloidal Gold Immunochromatographic Assay POCT Market Outlook & Forecast (2021-2033) Value (USD Million)

6.1. Global Colloidal Gold Immunochromatographic Assay POCT Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.1. Cardiovascular Testing

6.1.2. Infectious Disease Testing

6.1.3. Drug Abuse Testing

6.1.4. Pregnancy Testing

6.1.5. Other

6.2. Global Colloidal Gold Immunochromatographic Assay POCT Market Revenue (USD Million) and CAGR (%) by Types (2020-2032)

6.2.1. Indirect Method

6.2.2. Sandwich Method

6.2.3. Other

6.3. Global Colloidal Gold Immunochromatographic Assay POCT Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

7. Global Colloidal Gold Immunochromatographic Assay POCT Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global Colloidal Gold Immunochromatographic Assay POCT Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Application

7.2.3. North America Value (USD Million) (2020-2032) by Types

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Application

7.3.3. South America Value (USD Million) (2020-2032) by Types

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Application

7.4.3. Europe Value (USD Million) (2020-2032) by Types

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Types

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Application

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Types

8. Global Colloidal Gold Immunochromatographic Assay POCT Market Competition by Key Manufacturers

8.1. Global Colloidal Gold Immunochromatographic Assay POCT Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

8.2. Player's Concentration

8.2.1. Top 5 Manufacturers

8.2.2. Top 3 Manufacturers

8.3. Market Entropy

Global Colloidal Gold Immunochromatographic Assay POCT: Profiled Players Head Office and Area Served

8.4. Key Player Products/Services

8.4.1 Merger & Acquisitions and Expansion Plans

9. Company Profile

9.1. Abbott

9.1.1. Company Basic Information and Sales Area

9.1.2. Main Business/Business Overview

9.1.3. Product Portfolio

9.1.4. Financial

9.1.5. Recent Industry Insights

9.1.6. SWOT Analysis

9.2. Roche

9.2.1. Company Basic Information and Sales Area

9.2.2. Main Business/Business Overview

9.2.3. Product Portfolio

9.2.4. Financial

9.2.5. Recent Industry Insights

9.2.6. SWOT Analysis

9.3. QuidelOrtho

9.3.1. Company Basic Information and Sales Area

9.3.2. Main Business/Business Overview

9.3.3. Product Portfolio

9.3.4. Financial

9.3.5. Recent Industry Insights

9.3.6. SWOT Analysis

9.4. Wondfo Biotech

9.4.1. Company Basic Information and Sales Area

9.4.2. Main Business/Business Overview

9.4.3. Product Portfolio

9.4.4. Financial

9.4.5. Recent Industry Insights

9.4.6. SWOT Analysis

9.5. Getein Biotech

9.5.1. Company Basic Information and Sales Area

9.5.2. Main Business/Business Overview

9.5.3. Product Portfolio

9.5.4. Financial

9.5.5. Recent Industry Insights

9.5.6. SWOT Analysis

9.6. SD Biosensor

9.6.1. Company Basic Information and Sales Area

9.6.2. Main Business/Business Overview

9.6.3. Product Portfolio

9.6.4. Financial

9.6.5. Recent Industry Insights

9.6.6. SWOT Analysis

9.7. Orient Gene

9.7.1. Company Basic Information and Sales Area

9.7.2. Main Business/Business Overview

9.7.3. Product Portfolio

9.7.4. Financial

9.7.5. Recent Industry Insights

9.7.6. SWOT Analysis

9.8. ReLIA Biotech

9.8.1. Company Basic Information and Sales Area

9.8.2. Main Business/Business Overview

9.8.3. Product Portfolio

9.8.4. Financial

9.8.5. Recent Industry Insights

9.8.6. SWOT Analysis

9.9. ACON Biotech

9.9.1. Company Basic Information and Sales Area

9.9.2. Main Business/Business Overview

9.9.3. Product Portfolio

9.9.4. Financial

9.9.5. Recent Industry Insights

9.9.6. SWOT Analysis

9.10. Intec PRODUCT

9.10.1. Company Basic Information and Sales Area

9.10.2. Main Business/Business Overview

9.10.3. Product Portfolio

9.10.4. Financial

9.10.5. Recent Industry Insights

9.10.6. SWOT Analysis

9.11. Equinox Biotech Co

9.11.1. Company Basic Information and Sales Area

9.11.2. Main Business/Business Overview

9.11.3. Product Portfolio

9.11.4. Financial

9.11.5. Recent Industry Insights

9.11.6. SWOT Analysis

9.12. Shanghai Kehua Bio-engineering Co

9.12.1. Company Basic Information and Sales Area

9.12.2. Main Business/Business Overview

9.12.3. Product Portfolio

9.12.4. Financial

9.12.5. Recent Industry Insights

9.12.6. SWOT Analysis

9.13. Biotest Biotech

9.13.1. Company Basic Information and Sales Area

9.13.2. Main Business/Business Overview

9.13.3. Product Portfolio

9.13.4. Financial

9.13.5. Recent Industry Insights

9.13.6. SWOT Analysis

9.14. Assure Tech

9.14.1. Company Basic Information and Sales Area

9.14.2. Main Business/Business Overview

9.14.3. Product Portfolio

9.14.4. Financial

9.14.5. Recent Industry Insights

9.14.6. SWOT Analysis

9.15. Core Technology Co

9.15.1. Company Basic Information and Sales Area

9.15.2. Main Business/Business Overview

9.15.3. Product Portfolio

9.15.4. Financial

9.15.5. Recent Industry Insights

9.15.6. SWOT Analysis

9.16. Chongqing Zhongyuan BIO-TECHNOLOGY Co

9.16.1. Company Basic Information and Sales Area

9.16.2. Main Business/Business Overview

9.16.3. Product Portfolio

9.16.4. Financial

9.16.5. Recent Industry Insights

9.16.6. SWOT Analysis

9.17. Life Origin Biotech

9.17.1. Company Basic Information and Sales Area

9.17.2. Main Business/Business Overview

9.17.3. Product Portfolio

9.17.4. Financial

9.17.5. Recent Industry Insights

9.17.6. SWOT Analysis

9.18. Biotime

9.18.1. Company Basic Information and Sales Area

9.18.2. Main Business/Business Overview

9.18.3. Product Portfolio

9.18.4. Financial

9.18.5. Recent Industry Insights

9.18.6. SWOT Analysis

9.19. Anhui DEEPBLUE Medical Technology Co

9.19.1. Company Basic Information and Sales Area

9.19.2. Main Business/Business Overview

9.19.3. Product Portfolio

9.19.4. Financial

9.19.5. Recent Industry Insights

9.19.6. SWOT Analysis

9.20. Wantai BioPharm

9.20.1. Company Basic Information and Sales Area

9.20.2. Main Business/Business Overview

9.20.3. Product Portfolio

9.20.4. Financial

9.20.5. Recent Industry Insights

9.20.6. SWOT Analysis

9.21. Joinstar Biomedical Technology Co

9.21.1. Company Basic Information and Sales Area

9.21.2. Main Business/Business Overview

9.21.3. Product Portfolio

9.21.4. Financial

9.21.5. Recent Industry Insights

9.21.6. SWOT Analysis

9.22. J.H.Bio-Tec

9.22.1. Company Basic Information and Sales Area

9.22.2. Main Business/Business Overview

9.22.3. Product Portfolio

9.22.4. Financial

9.22.5. Recent Industry Insights

9.22.6. SWOT Analysis

9.23. Hangzhou Clongene Biotech Co

9.23.1. Company Basic Information and Sales Area

9.23.2. Main Business/Business Overview

9.23.3. Product Portfolio

9.23.4. Financial

9.23.5. Recent Industry Insights

9.23.6. SWOT Analysis

9.24. BIOHIT Healthcare,(Hefei) Co

9.24.1. Company Basic Information and Sales Area

9.24.2. Main Business/Business Overview

9.24.3. Product Portfolio

9.24.4. Financial

9.24.5. Recent Industry Insights

9.24.6. SWOT Analysis

9.25. Nanjing Vazyme Biotech Co

9.25.1. Company Basic Information and Sales Area

9.25.2. Main Business/Business Overview

9.25.3. Product Portfolio

9.25.4. Financial

9.25.5. Recent Industry Insights

9.25.6. SWOT Analysis

9.26. Shenzhen GLD Biotechnology Co

9.26.1. Company Basic Information and Sales Area

9.26.2. Main Business/Business Overview

9.26.3. Product Portfolio

9.26.4. Financial

9.26.5. Recent Industry Insights

9.26.6. SWOT Analysis

9.27. Hunan beixier Biotechnology Co

9.27.1. Company Basic Information and Sales Area

9.27.2. Main Business/Business Overview

9.27.3. Product Portfolio

9.27.4. Financial

9.27.5. Recent Industry Insights

9.27.6. SWOT Analysis

9.28. Shandong Kanghua Biotechnology Co

9.28.1. Company Basic Information and Sales Area

9.28.2. Main Business/Business Overview

9.28.3. Product Portfolio

9.28.4. Financial

9.28.5. Recent Industry Insights

9.28.6. SWOT Analysis

9.29. BOSON BIOTECH

9.29.1. Company Basic Information and Sales Area

9.29.2. Main Business/Business Overview

9.29.3. Product Portfolio

9.29.4. Financial

9.29.5. Recent Industry Insights

9.29.6. SWOT Analysis

9.30. AVE Science & Technology Co

9.30.1. Company Basic Information and Sales Area

9.30.2. Main Business/Business Overview

9.30.3. Product Portfolio

9.30.4. Financial

9.30.5. Recent Industry Insights

9.30.6. SWOT Analysis

10. Methodology/Research Approach

10.1. Research Programs/Material Type

10.2. Market Size Estimation

10.3. Market Breakdown and Data Triangulation

11. Data Sources

11.1. Secondary Sources

11.2. Primary Sources

List of Figures

24 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global Colloidal Gold Immunochromatographic Assay POCT Market

Figure 4: Global Colloidal Gold Immunochromatographic Assay POCT Market: Drivers

Figure 5: Global Colloidal Gold Immunochromatographic Assay POCT Market: Challenges

Figure 6: Global Colloidal Gold Immunochromatographic Assay POCT Market: Trends

Figure 7: Global Colloidal Gold Immunochromatographic Assay POCT Market: Opportunity

Figure 8: Global Colloidal Gold Immunochromatographic Assay POCT Market: Restraint

Figure 9: Global Colloidal Gold Immunochromatographic Assay POCT Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Application

Figure 11: Global Market Share (%) By Application (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Types

Figure 13: Global Market Share (%) By Types (2024)

Figure 14: Global Colloidal Gold Immunochromatographic Assay POCT Market Value (USD Million) By Region

Figure 15: Global Colloidal Gold Immunochromatographic Assay POCT Market Share (%) By: Regions (2024)

Figure 16: Top 5 Manufacturers

Figure 17: Top 3 Manufacturers

Figure 18: Global Market Value (USD Million) (2025-2032) By Application

Figure 19: Global Market Share (%) By Application (2032)

Figure 20: Global Market Value (USD Million) (2025-2032) By Types

Figure 21: Global Market Share (%) By Types (2032)

Figure 22: Global Colloidal Gold Immunochromatographic Assay POCT Market Value (USD Million) By Region

Figure 23: Global Colloidal Gold Immunochromatographic Assay POCT Market Share (%) By: Regions (2032)

Figure 24: Data Triangulation

List of Tables

113 items

Table 1: Market Segmentation Analysis

Table 2: Global Colloidal Gold Immunochromatographic Assay POCT Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 3: Global Colloidal Gold Immunochromatographic Assay POCT Revenue (USD Million) And Cagr (%) By Types (2020-2032)

Table 4: Global Colloidal Gold Immunochromatographic Assay POCT Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Application

Table 6: Global Market Share (%) By Application (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Types

Table 8: Global Market Share (%) By Types (2024)

Table 9: Global Colloidal Gold Immunochromatographic Assay POCT Market Value (USD Million) By Region

Table 10: Global Colloidal Gold Immunochromatographic Assay POCT Market Share (%) By Region

Table 11: North America Market Value (USD Million) (2020-2024) By Country

Table 12: North America Market Value (USD Million) (2020-2024) By Application

Table 13: North America Market Value (USD Million) (2020-2024) By Types

Table 14: Europe Market Value (USD Million) (2020-2024) By Country

Table 15: Europe Market Value (USD Million) (2020-2024) By Application

Table 16: Europe Market Value (USD Million) (2020-2024) By Types

Table 17: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 18: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 19: Asia Pacific Market Value (USD Million) (2020-2024) By Types

Table 20: South America Market Value (USD Million) (2020-2024) By Country

Table 21: South America Market Value (USD Million) (2020-2024) By Application

Table 22: South America Market Value (USD Million) (2020-2024) By Types

Table 23: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 24: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 25: Middle East & Africa Market Value (USD Million) (2020-2024) By Types

Table 26: Global Colloidal Gold Immunochromatographic Assay POCT Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 27: Global Colloidal Gold Immunochromatographic Assay POCT Market: Profiled Players Head Office And Area Served

Table 28: Key Players Global Colloidal Gold Immunochromatographic Assay POCT Market:

Table 29: Mergers & Acquisitions, Expansion Plans

Table 30: Abbott Basic Information And Sales Area

Table 31: Abbott. Products Portfolio

Table 32: Roche Basic Information And Sales Area

Table 33: Roche. Products Portfolio

Table 34: QuidelOrtho Basic Information And Sales Area

Table 35: QuidelOrtho. Products Portfolio

Table 36: Wondfo Biotech Basic Information And Sales Area

Table 37: Wondfo Biotech. Products Portfolio

Table 38: Getein Biotech Basic Information And Sales Area

Table 39: Getein Biotech. Products Portfolio

Table 40: SD Biosensor Basic Information And Sales Area

Table 41: SD Biosensor. Products Portfolio

Table 42: Orient Gene Basic Information And Sales Area

Table 43: Orient Gene. Products Portfolio

Table 44: ReLIA Biotech Basic Information And Sales Area

Table 45: ReLIA Biotech. Products Portfolio

Table 46: ACON Biotech Basic Information And Sales Area

Table 47: ACON Biotech. Products Portfolio

Table 48: Intec PRODUCT Basic Information And Sales Area

Table 49: Intec PRODUCT. Products Portfolio

Table 50: Equinox Biotech Co Basic Information And Sales Area

Table 51: Equinox Biotech Co. Products Portfolio

Table 52: Shanghai Kehua Bio-engineering Co Basic Information And Sales Area

Table 53: Shanghai Kehua Bio-engineering Co. Products Portfolio

Table 54: Biotest Biotech Basic Information And Sales Area

Table 55: Biotest Biotech. Products Portfolio

Table 56: Assure Tech Basic Information And Sales Area

Table 57: Assure Tech. Products Portfolio

Table 58: Core Technology Co Basic Information And Sales Area

Table 59: Core Technology Co. Products Portfolio

Table 60: Chongqing Zhongyuan BIO-TECHNOLOGY Co Basic Information And Sales Area

Table 61: Chongqing Zhongyuan BIO-TECHNOLOGY Co. Products Portfolio

Table 62: Life Origin Biotech Basic Information And Sales Area

Table 63: Life Origin Biotech. Products Portfolio

Table 64: Biotime Basic Information And Sales Area

Table 65: Biotime. Products Portfolio

Table 66: Anhui DEEPBLUE Medical Technology Co Basic Information And Sales Area

Table 67: Anhui DEEPBLUE Medical Technology Co. Products Portfolio

Table 68: Wantai BioPharm Basic Information And Sales Area

Table 69: Wantai BioPharm. Products Portfolio

Table 70: Joinstar Biomedical Technology Co Basic Information And Sales Area

Table 71: Joinstar Biomedical Technology Co. Products Portfolio

Table 72: J.H.Bio-Tec Basic Information And Sales Area

Table 73: J.H.Bio-Tec. Products Portfolio

Table 74: Hangzhou Clongene Biotech Co Basic Information And Sales Area

Table 75: Hangzhou Clongene Biotech Co. Products Portfolio

Table 76: BIOHIT Healthcare,(Hefei) Co Basic Information And Sales Area

Table 77: BIOHIT Healthcare,(Hefei) Co. Products Portfolio

Table 78: Nanjing Vazyme Biotech Co Basic Information And Sales Area

Table 79: Nanjing Vazyme Biotech Co. Products Portfolio

Table 80: Shenzhen GLD Biotechnology Co Basic Information And Sales Area

Table 81: Shenzhen GLD Biotechnology Co. Products Portfolio

Table 82: Hunan beixier Biotechnology Co Basic Information And Sales Area

Table 83: Hunan beixier Biotechnology Co. Products Portfolio

Table 84: Shandong Kanghua Biotechnology Co Basic Information And Sales Area

Table 85: Shandong Kanghua Biotechnology Co. Products Portfolio

Table 86: BOSON BIOTECH Basic Information And Sales Area

Table 87: BOSON BIOTECH. Products Portfolio

Table 88: AVE Science & Technology Co Basic Information And Sales Area

Table 89: AVE Science & Technology Co. Products Portfolio

Table 90: Global Market Value (USD Million) (2025-2032) By Application

Table 91: Global Market Share (%) By Application (2032)

Table 92: Global Market Value (USD Million) (2025-2032) By Types

Table 93: Global Market Share (%) By Types (2032)

Table 94: Global Colloidal Gold Immunochromatographic Assay POCT Market Value (USD Million) By Region

Table 95: Global Colloidal Gold Immunochromatographic Assay POCT Market Share (%) By Region (2025-2032)

Table 96: North America Market Value (USD Million) (2025-2032) By Country

Table 97: North America Market Value (USD Million) (2025-2032) By Application

Table 98: North America Market Value (USD Million) (2025-2032) By Types

Table 99: Europe Market Value (USD Million) (2025-2032) By Country

Table 100: Europe Market Value (USD Million) (2025-2032) By Application

Table 101: Europe Market Value (USD Million) (2025-2032) By Types

Table 102: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 103: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 104: Asia Pacific Market Value (USD Million) (2025-2032) By Types

Table 105: South America Market Value (USD Million) (2025-2032) By Country

Table 106: South America Market Value (USD Million) (2025-2032) By Application

Table 107: South America Market Value (USD Million) (2025-2032) By Types

Table 108: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 109: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 110: Middle East & Africa Market Value (USD Million) (2025-2032) By Types

Table 111: Research Programs/Design For This Report

Table 112: Key Data Information From Secondary Sources

Table 113: Key Data Information From Primary Sources

FAQs

1. What is the current Colloidal Gold Immunochromatographic Assay POCT market size?

The Colloidal Gold Immunochromatographic Assay POCT market size was estimated at roughly USD 1.3 billion in 2023, driven by expanding point‑of‑care diagnostics in infectious disease screening, chronic‑disease monitoring, and rapid testing across hospital and community settings.

2. What is the projected growth rate and forecast through 2032?

Analysts project a compound annual growth rate of 6.2 % for the Colloidal Gold Immunochromatographic Assay POCT market, expanding the market to about USD 2.4 billion by 2032, propelled by emerging pathogen threats and increasing demand for decentralized testing.

3. Which factors are the primary drivers of market expansion?

Key drivers include rising prevalence of infectious diseases, government initiatives promoting point‑of‑care testing, cost‑effective nature of colloidal‑gold strips, and advancements in multiplexing that enable simultaneous detection of multiple biomarkers, thereby improving clinical workflow efficiency.

4. What challenges could impede market growth?

Major challenges involve stringent regulatory approval timelines, limited stability of gold nanoparticles under extreme temperatures, competition from fluorescence‑based assays offering higher sensitivity, and supply chain constraints for high‑purity reagents, which may raise production costs.

5. Which regions are leading the market and why?

North America leads due to robust healthcare infrastructure and early adoption of rapid diagnostics, while Asia‑Pacific follows with the fastest growth, fueled by large patient populations, expanding public‑health programs, and rising investment in point‑of‑care technologies.

6. Who are the top competitive players in this space?

Leading companies include Abbott Laboratories, Roche Diagnostics, Bio‑Rad Laboratories, Qiagen, and Shenzhen Lifotronics, each leveraging proprietary gold‑nanoparticle chemistries, extensive distribution networks, and strategic partnerships to capture market share across diverse diagnostic segments.

7. What future opportunities are emerging for the market?

The future outlook highlights opportunities from integration with digital health platforms, development of quantitative readout devices, expansion into veterinary and environmental testing, and the creation of next‑generation assays that combine CRISPR‑based amplification with colloidal‑gold detection for ultra‑sensitive results.

8. How is technology influencing assay performance?

Advances in nanofabrication improve particle uniformity, enhancing signal intensity and reproducibility; microfluidic integration reduces assay time to under five minutes; and AI‑enabled image analysis provides objective interpretation, collectively raising sensitivity, specificity, and user friendliness of POCT devices.

9. What is the regulatory landscape for these assays?

The market navigates FDA 510(k) clearance in the U.S., CE marking under EU In‑Vitro Diagnostic Regulation, and comparable pathways in China and Japan; compliance demands rigorous clinical validation, quality‑system adherence, and post‑market surveillance to maintain market access.

Contact for Full Report

Loading report content...

Market Snapshot

Loading chart…

Colloidal Gold Immunochromatographic Assay POCT Market Overview

Loading chart…

Report Overview

Report Attribute	Details
Market size value in 2025	2.04 billion
Revenue forecast in 2033	3.56 billion
Growth rate	CAGR of 7.2% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Abbott; Roche; QuidelOrtho; Wondfo Biotech; Getein Biotech; SD Biosensor; Orient Gene; ReLIA Biotech; ACON Biotech; Intec PRODUCT; Equinox Biotech Co; Shanghai Kehua Bio-engineering Co; Biotest Biotech; Assure Tech; Core Technology Co; Chongqing Zhongyuan BIO-TECHNOLOGY Co; Life Origin Biotech; Biotime; Anhui DEEPBLUE Medical Technology Co; Wantai BioPharm; Joinstar Biomedical Technology Co; J.H.Bio-Tec; Hangzhou Clongene Biotech Co; BIOHIT Healthcare,(Hefei) Co; Nanjing Vazyme Biotech Co; Shenzhen GLD Biotechnology Co; Hunan beixier Biotechnology Co; Shandong Kanghua Biotechnology Co; BOSON BIOTECH; AVE Science & Technology Co
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options